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■ Introduction
Non-muscle-invasive bladder cancer (NMIBC) represents the most common disease state for patients with newly diagnosed bladder cancer. 1 Those with high-grade (HG) tumors are at significant risk for both recurrence and progression. 2, 3 Bacillus Calmette-Guerin (BCG) represents the current preferred management. [4] [5] [6] Nonetheless, approximately 30% of patients will not respond to BCG; among those who demonstrate an initial response, more than 50% will experience recurrence and progression during long-term follow-up. 7 The optimal management of patients with persistent or recurrent tumor after BCG remains controversial. 8 Although radical cystectomy provides cancer eradication, 9 many patients are elderly, have significant comorbidities with an attendant diminished performance status, and often are unwilling to undergo radical extirpative surgery. Nonextirpative treatment options are available, but studies to date have included relatively small patient numbers and used varied definitions of treatment success 8, [10] [11] [12] [13] [14] [15] [16] Indeed, the US Food and Drug Administration (FDA) and genitourinary oncology community agree that scant progress has been made in the management of this disease since the initial approval of BCG. [17] [18] [19] Thus an effective alternative to radical cystectomy for patients with disease recurrence after BCG treatment remains an important unmet clinical need. 17 Recombinant intravesical interferon alfa-2b protein (IFNα-2b; Intron A; Merck, Kenilworth, NJ) demonstrated promising initial clinical results in NMIBC. 20, 21 Intravesical IFNα-2b gene delivery offers a novel approach and increases the duration of exposure to IFNα-2b. Recombinant adenovirus (rAd)-IFNα-2b is a replicationdeficient adenovirus-based gene transfer vector that encodes the human IFNα-2b gene. [22] [23] [24] Syn3, a polyamide surfactant, is incorporated into the drug formulation (rAd-IFNα/Syn3; Instiladrin, FKD Therapies Oy, Kuopio, Finland) 25 to enhance adenoviral transduction of the bladder lining. Dramatic enrichment of rAd-IFNα gene transfer and expression has been shown with Syn3 in both normal urothelium and human urothelial carcinoma that grows in mice. [22] [23] [24] [25] rAd-IFNα-2b gene therapy mimics the physiologic events associated with viral infection, which results in local rather than systemic IFNα-2b production and subsequent tumor regression. 22 A phase I dose-ascending study of rAd-IFNα/Syn3 was performed for patients with BCG-refractory and relapsing NMIBC. 26 Dose-dependent adenoviral gene transfer and urine concentrations of IFNα-2b were confirmed. Of 14 patients treated with dose levels of rAd-IFNα/Syn3 that resulted in measurable urine IFNα, six (43%) were free from recurrence at 3 months and had no dose-limiting toxicity, and two patients remained disease free at 29 and 39 months. 26 These provocative findings, predominantly at the two highest doses, prompted this phase II study, designed to evaluate the efficacy and safety of intravesical rAd-IFNα/Syn3 for patients with HG NMIBC refractory to, or with relapse after, BCG.
■ Methods

■ Study design
This randomized, open-label, parallel-arm study was conducted across 13 centers in the United States between November 5, 2012, and April 8, 2015. The protocol, administrative oversight, and accrual timelines were designed and conducted by the Society of Urologic Oncology Clinical Trials Consortium. The study protocol and informed consent form were reviewed and approved by the respective responsible site institutional review boards and biosafety committees.
■ Patients
The trial was designed to enroll 40 patients unable or unwilling to undergo radical cystectomy, and there were two dosage groups of 20 patients each. Eligible patients were 18 years or older and had HG BCGrefractory or relapsed NMIBC, including papillary NMIBC alone (Ta or T1), carcinoma in situ (CIS) alone, or a combination of CIS and papillary disease. BCG-refractory disease was defined as the inability to achieve a disease-free state at 6 months after adequate induction BCG therapy with either maintenance or reinduction at 3 months. Adequate induction was defined as a minimum of five of six treatments, and adequate maintenance was defined as a minimum of two of three treatments. BCG relapse was defined as recurrence within 1 year after a complete response to adequate BCG treatment (at least five and two instillations). Patients were required to have undergone visually complete resection of papillary lesions by transurethral resection of bladder tumors. Patients could not have received intravesical therapy within 3 months before beginning study treatment, with the exception of cytotoxic agents when administered as a single instillation immediately after a transurethral resection. All participants who entered the study provided written or oral informed consent.
■ Random assignment and masking
Patients were assigned by computergenerated random assignment, with a constrained 1:1 sequence, to receive either low-dose (1 × 10 11 viral particles [vp]/mL) or high-dose (3 × 10 11 vp/mL) rAd-IFNα/ Syn3. These doses were the most promising observed in the phase I study. The total doses administered were 7.5 × 10 12 vp in the low-dose group and 2.25 × 10 13 vp in the high-dose group. Treatment allocation was performed centrally with a block size of two for all patients who had successfully completed screening, with the constraint that the first four patients at each site were balanced between cohorts.
■ Procedures
rAd-IFNα/Syn3 in 75 mL was administered intravesically through a urethral catheter, with a planned retention time of 1 hour; an anticholinergic treatment was allowed to relieve urinary urgency and permit adequate retention. Patients without recurrence of HG disease at months 3, 6, and 9, as evaluated by cytology, cystoscopy, and biopsy (if clinically indicated) were then retreated at months 4, 7, and 10. At 12 months, a final efficacy evaluation was performed. This evaluation included a protocol-mandated biopsy from the site of the index tumor and at least five random biopsies, including the bladder dome, trigone, right and left lateral wall, posterior wall, and prostatic urethra in men with positive cytology or prior disease in this region.
During the study, patients were contacted weekly by phone for the first month after each treatment on days 7, 14 (of months 7 and 10 only), 21, and 28 (± 1 day) to provide information about adverse events (AEs) and concomitant medication use. Assessments for treatment failure were made between 14 and 7 days before retreatment. Patients who were withdrawn from treatment before study completion underwent a safety assessment at least 30 days after last administration of the study drug. All patients are being monitored in a 3-year long-term follow-up period to (1) determine recurrence of HG disease in those patients with a complete response and (2) to assess the long-term impact of treatment with rAd-IFNα/Syn3.
■ End points
The primary end point was freedom from HG disease recurrence at 12 months, defined by a negative for cause or end of study biopsy. Secondary end points included response to treatment, defined as no evidence of recurrence of HG disease at 3, 6, and 9 months; incidence and time to cystectomy; and concentration of IFNα-2b in the urine. Safety assessments included physical examination, monitoring of vital signs, ECG, and standard clinical chemistry, hematology, and urinalysis assessments (performed by local laboratories). Safety end points include type, incidence, relatedness, and severity of AEs and severe (≥ grade 3) AEs (SAEs), as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).
■ Statistical analyses
We determined that a cohort of 20 patients would be sufficient to give an 80% probability of rejection of a HG recurrence-free survival (RFS) rate of 10% with an exact 5% one-sided test when the true HG RFS rate was 35%. The operating characteristics for this Fleming design were calculated • Evaluation included a protocol-mandated biopsy from the site of the index tumor and at least five random biopsies, including the bladder dome, trigone, right and left lateral wall, posterior wall, and prostatic urethra in men with positive cytology or prior disease in this region.
• Patients who were withdrawn from treatment before study completion underwent a safety assessment at least 30 days after last administration of the study drug.
exactly with the binomial distribution described by A'Hern. 27 The hypothesisthat the response rate was equal to or less than the reference rate-was rejected if five or more of the 20 patients achieved HG RFS at 12 months. The proportion of patients who achieved HG RFS at 3, 6, 9, and 12 months was reported for each dose group, together with an exact 90% CI for the proportion. The time to HG recurrence or death was summarized with the Kaplan-Meier method. Analyses were performed with SAS (version 9 or later; SAS Institute, Cary, NC). Both the safety and efficacy (modified intention-to-treat) analysis sets included all patients who received at least one dose of rAd-IFNα/Syn3. A data monitoring committee oversaw the study according to the data monitoring plan.
■ Analytical assays and sample testing
All analytical assays were developed and validated. Samples were tested according to good laboratory practices methods at Covance Laboratories Ltd (Harrogate, United Kingdom).
■ Results
Patient disposition is shown in Figure 1 . Baseline characteristics are listed in Table 1 Table 2 ). Offschedule disease assessments did not affect findings. The median time to HG recurrence or death was 6.5 months (90% CI, 3.52 to 12.78 months); the median time to HG recurrence was 3.52 months (90% CI, 3.02 to 12.78 months) for the low-dose group and was 11.73 months (90% CI, 5.88 months to not evaluable) for the highdose group. When patient subgroups and secondary end points were considered in exploratory analyses, the 12-month HG RFS rates were broadly similar for men and women, for younger and older patients, for refractory or relapsed NMIBC, for CIS only or papillary tumors and CIS, and for patients with Ta and T1 disease only (Table 2) . Interestingly, of the 14 patients who were recurrence free at 12 months, 10 (71%) of the 14 had an antiadenovirus antibody response (defined as four times the predose titer), compared with 11 (24%) of 25 who experienced recurrence.
Significant levels of urine IFNα-2b were measurable in all patients in month 1 at days 2, 4, and 12 (Table 3 ). Of those patients who received a second dose, measurable IFNα-2b urine concentrations were noted in month 4 on days 2 and 4 after drug administration. Urine IFNα-2b concentrations did not appear to correlate with dose or clinical response.
In long-term follow-up, seven patients (18%) who withdrew from the study because of HG disease recurrence within the 12-month study period died at a median of 16 months (range, 2 to 26 months) after the withdrawal date.
There is no indication that these deaths were treatment related. The cause of death was unknown in four patients, whereas two died as a result of progressive bladder cancer and one died as a result of liver failure unrelated to treatment 17 months after withdrawal from the study. The four patients for whom the cause of death is unknown were being observed locally after they completed their end-of-study evaluation. Fourteen patients (35%) who experienced an HG recurrence within the first year underwent a radical cystectomy at a median of 9 months (range, 4 to 28 months) from day 1 of month 1.
Patients are being monitored for 3 years to collect long-term follow-up data. Of the 14 patients who remained disease free at 12 months, additional follow-up data are being collected for 11; 3 withdrew from the study. Nine of these 11 patients are alive, and eight remained disease-free during a period of 15 to more than 36 months (Table 4 ). Two patients experienced HG recurrence at 21 and 28 months, respectively, from the start of treatment. One of these patients who experienced progression to muscle invasion underwent a radical cystectomy 31 months after the initiation ■ Duration of HG RFS represent the number of months from day 1 that a complete response within the bladder has been documented based on yearly reports. Three patients withdrew from the study shortly after the 1-month end-of-study evaluation. Two patients had recurrence of HGD at 21 and 28 months from day 1. One of these patients underwent a cystectomy but later died. One patient died of an upper tract tumor without a bladder recurrence. CIS, carcinoma in situ; CR, complete response; HG, high-grade; HGD, high-grade disease; rAd-IFNα/Syn3, recombinant adenovirus interferon alfa protein/Syn3 (a nonreplicating recombinant adenovirus gene transfer vector for patients with HG bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer); RFS, relapse-free survival; Ta, papillary urothelial carcinoma confined to the mucosa; T1, micro-invasive urothelial carcinoma invasive into lamina propria but not muscularis propria. 27 Overall, the limited number of patients studied in previous trials, as well as the modest RFS with treatment despite a less stringently defined eligibility, illustrates the unmet need for effective and evidence-based second-line therapy for patients with BCG-unresponsive disease that improves disease-specific patient outcomes and avoids cystectomy.
We recognize that this study is limited by its relatively small sample size and the lack of a comparative treatment arm. However, the trial was designed to determine optimal dosing and to provide preliminary efficacy to develop a definitive single-arm registration study. 12 Few agents have actually gone beyond phase I and II development, so it is readily apparent that the traditional pathway for drug registration does not work for NMIBC. This concern was addressed through deliberations among the Society of Urologic Oncology, American Urological Association, and FDA, with the consensus that a single-arm trial with a mixed population of papillary disease and CIS was appropriate for the BCG-unresponsive population, given that a minimal threshold of patients who had some component of CIS was met. 17 Although the clinical impact of rAd-IFNα is encouraging, the mechanisms that mediate its antitumor activity remain undefined. In preclinical studies, IFNα and rAd-IFN beta inhibited angiogenesis, 28, 29 and IFNα directly induced apoptosis in human bladder cancer cells by inducing autocrine tumor necrosis factor-related apoptosisinducing ligand production. 30 Furthermore, rAd-IFNα overcame resistance to the IFNα protein in vitro and in animal models. 22 It is now well established that IFNα controls dendritic cell maturation and antigen presentation and promotes tumor recognition by T cells and natural killer cells, and that these effects likely play more important roles in tumor growth inhibition than the direct effects of IFNα on tumor cells. [31] [32] [33] Like IFN gamma, IFNα induces programmed death ligand 1 expression, 34 which may limit tumor immune recognition and almost certainly inhibits T-cell activation; this may explain the resistance to rAd-IFNα by some of the bladder cancers treated in this study. Combination therapy with IFNα and an anti-programmed death 1 inhibitor was more efficacious in preclinical studies than either agent alone at inhibition of melanoma tumor growth, and combination trials in NMIBC are under consideration. 34 Finally, studies have demonstrated that local delivery of IFNα is better than systemic delivery to enhance tumor immune recognition, and viral transduction itself provides an important signal for kickstarting the immune system. Thus, in addition to serving as a bioreactor for sustained IFNα production (in contrast to the transient levels measured after intravesical instillation of the IFNα protein), 24 IFNα gene therapy should produce unique, desirable effects on antitumor immunity through local (as opposed to systemic) IFNα production and viral activation of intracellular pattern receptors. Thus, there are multiple reasons to explain the enhanced efficacy of rAd-IFNα compared with IFNα-2b in the treatment of refractory NMIBC. 35 In summary, rAd-IFNα/Syn3 was well tolerated and demonstrated promising efficacy for patients with HG NMIBC after BCG therapy. A phase III trial of high-dose rAd-IFNα/Syn3, which provided longer median HG RFS and equivalent biosafety, is ongoing.
Key points
• Overall, the limited number of patients studied in previous trials, as well as the modest RFS with treatment despite a less stringently defined eligibility, illustrates the unmet need for effective and evidence-based second-line therapy for patients with BCGunresponsive disease that improves disease-specific patient outcomes and avoids cystectomy.
• We recognize that this study is limited by its relatively small sample size and the lack of a comparative treatment arm.
• Although the clinical impact of rAd-IFNα is encouraging, the mechanisms that mediate its antitumor activity remain undefined.
• It is now well established that IFNα controls dendritic cell maturation and antigen presentation and promotes tumor recognition by T cells and natural killer cells, and that these effects likely play more important roles in tumor growth inhibition than the direct effects of IFNα on tumor cells.
• Combination therapy
with IFNα and an antiprogrammed death 1 inhibitor was more efficacious in preclinical studies than either agent alone at inhibition of melanoma tumor growth, and combination trials in NMIBC are under consideration.
